Clarithromycin

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 92-95

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ASTEMIZOLE; AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; CLATHROMYCIN; DRUG METABOLITE; ERYTHROMYCIN; ETHAMBUTOL; ISONIAZID; PIMOZIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TERFENADINE; THIOACETAZONE; VANCOMYCIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERIAL STRAIN; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HELICOBACTER PYLORI; HUMAN; HYPOGLYCEMIA; JAUNDICE; LIVER TOXICITY; MELTING POINT; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MONOTHERAPY; MYCOBACTERIOSIS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TORSADE DES POINTES; TUBERCULOSIS; VOMITING;

ANIMALS; ANTITUBERCULAR AGENTS; CLARITHROMYCIN; HUMANS; MICE; RATS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249112492     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70005-2     Document Type: Review

References (21)

1. Fernandes P., et al. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 33 (1989) 1531-1534
2. Andini N., and Nash K. Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother 50 (2006) 2560-2562
3. Nash K. Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38). Antimicrob Agents Chemother 47 (2003) 3053-3060
4. Falzari K., et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis. Antimicrob Agents Chemother 49 (2005) 1447-1454
5. Rastogi N., et al. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33 (1996) 167-175
6. Gorzynski E., et al. Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 33 (1989) 591-592
7. Brown B., et al. Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system. Antimicrob Agents Chemother 36 (1992) 1987-1990
8. Truffot-Pernot C., et al. Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 39 (1995) 2827-2828
9. Rodriguez-Diaz J., et al. Synergic activity of fluoroquinolones and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 21 (2003) 354-356
10. Bosne-David S., et al. Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 46 (2000) 391-395
11. Hoffner S., et al. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant My-cobacterium tuberculosis. J Antimicrob Chemother 40 (1997) 885-888
12. Bhusal Y., et al. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 26 (2005) 292-297
13. Cavalieri S., et al. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 39 (1995) 1542-1545
14. Mor N., and Esfandiari A. Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 41 (1997) 2035-2036
15. Luna-Herrera J., et al. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 39 (1995) 2692-2695
16. Chan E., and Iseman M. Current medical treatment for tuberculosis. Br Med J 325 (2002) 1282-1286
17. Di Perri G., and Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?. J Antimicrob Chemother 54 (2004) 593-602
18. Hoffman H., et al. Influence of macrolide susceptibility on efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 47 (2003) 739-746
19. Chu S., et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother 36 (1992) 2447-2453
20. Kohno Y., et al. Comparative pharmacokinetics of clarithromycin (TE-031), a new macrolide antibiotic, and erythromycin in rats. Antimicrob Agents Chemother 33 (1989) 751-756
21. http://www.medsafe.govt.nz/Profse/Datasheet/k/KlacidIVinj.htm